These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29855525)

  • 1. Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513.
    Wong YH; Kumar A; Liew CW; Tharakaraman K; Srinivasaraghavan K; Sasisekharan R; Verma C; Lescar J
    Sci Rep; 2018 May; 8(1):8449. PubMed ID: 29855525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes.
    Rajamanonmani R; Nkenfou C; Clancy P; Yau YH; Shochat SG; Sukupolvi-Petty S; Schul W; Diamond MS; Vasudevan SG; Lescar J
    J Gen Virol; 2009 Apr; 90(Pt 4):799-809. PubMed ID: 19264660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display.
    Frei JC; Kielian M; Lai JR
    Virology; 2015 Nov; 485():371-82. PubMed ID: 26339794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism.
    Thullier P; Demangel C; Bedouelle H; Mégret F; Jouan A; Deubel V; Mazié JC; Lafaye P
    J Gen Virol; 2001 Aug; 82(Pt 8):1885-1892. PubMed ID: 11457994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
    Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.
    Lisova O; Belkadi L; Bedouelle H
    J Mol Recognit; 2014 Apr; 27(4):205-14. PubMed ID: 24591178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human monoclonal single-chain antibodies specific to dengue virus envelope protein.
    Saokaew N; Poungpair O; Panya A; Tarasuk M; Sawasdee N; Limjindaporn T; Chaicumpa W; Yenchitsomanus P
    Lett Appl Microbiol; 2014 Mar; 58(3):270-7. PubMed ID: 24266517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.
    Hiramatsu K; Tadano M; Men R; Lai CJ
    Virology; 1996 Oct; 224(2):437-45. PubMed ID: 8874504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection.
    Xu M; Züst R; Toh YX; Pfaff JM; Kahle KM; Davidson E; Doranz BJ; Velumani S; Tukijan F; Wang CI; Fink K
    J Virol; 2016 Dec; 90(24):11122-11131. PubMed ID: 27707930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.
    Midgley CM; Flanagan A; Tran HB; Dejnirattisai W; Chawansuntati K; Jumnainsong A; Wongwiwat W; Duangchinda T; Mongkolsapaya J; Grimes JM; Screaton GR
    J Immunol; 2012 May; 188(10):4971-9. PubMed ID: 22491255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Engineered N-Glycosylated Dengue Envelope Protein Domain III Facilitates Epitope-Directed Selection of Potently Neutralizing and Minimally Enhancing Antibodies.
    Nilchan N; Kraivong R; Luangaram P; Phungsom A; Tantiwatcharakunthon M; Traewachiwiphak S; Prommool T; Punyadee N; Avirutnan P; Duangchinda T; Malasit P; Puttikhunt C
    ACS Infect Dis; 2024 Aug; 10(8):2690-2704. PubMed ID: 38943594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a monoclonal antibody specific to envelope domain III with broad-spectrum detection of all four dengue virus serotypes.
    Kim SH; Kim YN; Truong TT; Thu Thuy NT; Mai LQ; Jang YS
    Biochem Biophys Res Commun; 2016 May; 473(4):894-898. PubMed ID: 27059141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential dengue cross-reactive and neutralizing antibody responses in BALB/c and Swiss albino mice induced by immunization with flaviviral vaccines and by infection with homotypic dengue-2 virus strains.
    Lim CS; Chua JJ; Wilkerson J; Chow VT
    Viral Immunol; 2006; 19(1):33-41. PubMed ID: 16553548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and Functional Characterization of a Cross-Reactive Dengue Virus Neutralizing Antibody that Recognizes a Cryptic Epitope.
    Li J; Watterson D; Chang CW; Che XY; Li XQ; Ericsson DJ; Qiu LW; Cai JP; Chen J; Fry SR; Cheung STM; Cooper MA; Young PR; Kobe B
    Structure; 2018 Jan; 26(1):51-59.e4. PubMed ID: 29249606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.
    Tang CT; Li PC; Liu IJ; Liao MY; Chiu CY; Chao DY; Wu HC
    PLoS Negl Trop Dis; 2015; 9(7):e0003903. PubMed ID: 26135599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.
    Gromowski GD; Barrett AD
    Virology; 2007 Sep; 366(2):349-60. PubMed ID: 17719070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody.
    Cockburn JJ; Navarro Sanchez ME; Fretes N; Urvoas A; Staropoli I; Kikuti CM; Coffey LL; Arenzana Seisdedos F; Bedouelle H; Rey FA
    Structure; 2012 Feb; 20(2):303-14. PubMed ID: 22285214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries.
    Moreland NJ; Susanto P; Lim E; Tay MYF; Rajamanonmani R; Hanson BJ; Vasudevan SG
    Int J Mol Sci; 2012; 13(3):2618-2635. PubMed ID: 22489114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and characterization of a monoclonal antibody that cross-reacts with the envelope protein from the four dengue virus serotypes.
    León-Juárez M; García-Cordero J; Santos-Argumedo L; Romero-Ramírez H; García-Machorro J; Bustos-Arriaga J; Gutiérrez-Castañeda B; Sepúlveda NV; Mellado-Sánchez G; Cedillo-Barrón L
    APMIS; 2013 Sep; 121(9):848-58. PubMed ID: 23331315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.